[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"leishmaniasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:leishmaniasis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,147,200],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":4,"leadSponsor":44,"locationsCount":47},"100083481","diagnosis-and-treatment-of-leishmania-infections-100083481",false,"NCT00344188","Diagnosis and Treatment of Leishmania Infections","Host Response to Infection and Treatment in Leishmania Infection of Humans","* INCLUSION CRITERIA:\n* Individuals aged 3 to 100 years.\n* Diagnosis of leishmaniasis:\n\nA: Biopsy proven\n\nOR\n\nB: Likely diagnosis of leishmaniasis based on :\n\nEpidemiologic exposure, clinical manifestations, and time course\n\n* Willingness to allow samples to be stored for future research.\n* Ability to provide informed consent.\n\nEXCLUSION CRITERIA:\n\nAny condition that, in the judgment of the investigator, may put the participant at undue risk or make them unsuitable for participation in the study.","ALL","3 Years","100 Years",{"count":20,"type":21},289,"ESTIMATED","OBSERVATIONAL","Patients admitted on this protocol must have an active Leishmania infection. The major objectives of the protocol are to diagnose and classify the Leishmania infection and to provide species-based therapy to study the natural history of the treated infection and further understand host and species characteristics that lead to resistant or relapsing disease. As part of the standard evaluation of these patients, biopsies to obtain parasite and host tissue will be obtained. The host response before and after therapy will be assessed to address broader questions related to diagnosis, disease pathogenesis, and response to therapy. Careful observations of the patients clinical and immunologic responses to therapy will be made, as well as long-term follow-up of these changes. It is anticipated that the patients will receive optimal clinical care for their infections and that the specimens collected from them will prove to be valuable reagents for the laboratory studies of the host responses unique to leishmanial infections.\n\nBased on the nature of the disease and the recommended treatment, subjects will receive clinically appropriate treatment. Patients will undergo a limited physical examination to assess general condition, respiratory status, and skin condition. Following treatment patients are seen at 3 months and 12 months. Blood, lesion swabs, mucosal swabs, microbiopsies and\u002For skin biopsies will be collected for research evaluations. There will also be a mandatory check in (photos, telephone or telehealth visit) at 6 months. All of these post treatment timepoints are used to follow the course of the disease and management. Additional visits may be scheduled for clinically indicated procedures as guided by clinical status and need for evaluation. Samples collected from clinical evaluations may also be studied for research purposes and the results will be collected as part of this protocol. Participants enrolled can be assessed using an approved virtual platform. Study visits can be performed remotely if outside physicians are able to submit study specimens (blood samples, lesion and mucosal swabs).\n\nThe final study visit will typically be at 1 year following successful treatment. Blood will be collected, and swabs\u002Fmicrobiopsies may be collected for research evaluations at this visit. Follow up visits beyond the 1-year post-treatment point may occur on an annual basis if clinically necessary, as deemed by the investigator.",[25,26,27,28,29],"Kinetoplastid","Skin Diseases, Parasitic","Parasitic Diseases","Leishmaniasis","Protozoa",[31,32,33,34,35,36],"mucosal leishmaniasis","Visceral leishmaniasis","Natural History","Mucocutaneous Leishmaniasis","Leishmania","CUTANEOUS LEISHMANIASIS","RECRUITING","2026-08-11",{"date":40,"type":41},"2026-08-12","ACTUAL",{"date":43,"type":41},"2001-11-30",{"name":45,"class":46},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":60,"conditions":61,"keywords":119,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":47},"100620537","risk-assessment-of-community-spread-of-multiple-endemic-infectious-diseases-in-a-one-health-perspective-100620537","NCT07358910","Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","RACSMEI","Inclusion Criteria:\n\n* Residency in the village for more than 6 months;\n* Age between 2 and 75 years old at the time of inclusion;\n* For adults: provision of written consent;\n* For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;\n\nExclusion Criteria:\n\n* Unable to understand or consent;\n* Under guardianship or deprived of liberty;\n* Medical conditions that impede survey participation;\n* Refusal to participate in the study.",true,"2 Years","75 Years",{"count":59,"type":21},10000,"RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.\n\nRACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.\n\nMathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.",[62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,28,111,112,113,114,115,116,117,118],"Dengue","Chikungunya","Zika Virus Infection","Japanese Encephalitis","West Nile Virus","Tick-borne Encephalitis (TBE)","Severe Fever With Thrombocytopenia Syndrome","Nipah Virus Infection","Hantavirus Infections","Hepatitis E","Brucellosis","Q Fever","Leptospirosis","Melioidosis","Influenza A and B","Malaria","Yellow Fever","Mayaro Fever","Usutu Virus Infection","Oropouche Fever","Rift Valley Fever","Arenavirus Infections","Measles","Mumps","Rubella","Human Papilloma Virus (HPV)","Rotavirus Disease","Pertussis","Diphteria","Tetanus","Varicella","Hepatitis A","Norovirus Infections","Enterovirus","Adenovirus","Rhinovirus","Parvovirus","Respiratory Syncytial Virus (RSV)","Cytomegalovirus","Epstein Barr Virus","Salmonella Typhi","Vibrio Cholerae","Legionella Pneumophila Pneumonia","Mycoplasma","Chlamydia","Lymphatic Filariasis","Toxoplasma Gondii","Giardiasis","Entamoeba Histolytica","Strongyloides Stercoralis Infection","Ascaris Lumbricoides","Trichuris Trichiura","Clonorchis Sinensis","Opisthorchis Viverrini","Schistosomiasis","Streptococcus Pneumoniae","Meningitis",[120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136],"Infectious disease","One Health","Population-based survey","Nationally representative survey","Seroepidemiology","Multiplex serology","Seroprevalence","Vector-borne diseases","Zoonoses","Vaccine-preventable diseases","Neglected tropical diseases","Transmission dynamics","Force of infection","Mathematical modelling","Spatial epidemiology","Precision public health","Cambodia","2026-01-14",{"date":139,"type":41},"2026-01-22",{"date":141,"type":41},"2025-12-18",{"date":143,"type":21},"2027-09-30",{"name":145,"class":146},"Institut Pasteur du Cambodge","OTHER",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":155,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":158,"phases":159,"briefSummary":161,"conditions":162,"keywords":175,"overallStatus":190,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":47},"100582154","serological-measurement-of-montpellier-professionals-contacts-with-infectious-agents-responsible-for-animal-borne-diseases-100582154","NCT06859619","Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases","Seroprevalence of Zoonotic and Arboviral Emerging Infections in Exposed Agents from the City of Montpellier: a Transversal Study.","SEZAM","Inclusion Criteria:\n\n* Age 18 or over\n* Consultant in an infectious diseases department\n* Have given written consent to participate in the study\n* Working for the City or Metropolis of Montpellier in the Zoo, Espaces Vert or Ecolothèque departments.\n\nExclusion Criteria:\n\n* \\- Pregnant and breast-feeding women\n* Persons benefiting from legal protection measures (guardianship, curatorship, safeguard of justice)\n* Participants who are not fluent in French and who do not have a support person capable of reading French.\n* Persons unable to express their consent.\n* Persons participating in another research project with an exclusion period still in progress.\n* Persons not affiliated to a social security scheme or not benefiting from such a scheme.","18 Years",{"count":157,"type":21},183,"INTERVENTIONAL",[160],"NA","Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments). Most of these diseases are found in certain tropical zones, but global warming and increased international trade are modifying their geographical distribution, with a gradual trend towards temperate regions. A number of these pathogens have already been detected in Occitania, including dengue fever, West Nile, leishmaniasis and Q fever. Given the region's high mosquito population and favorable climatic conditions, other zoonoses have a strong potential to appear in the region, or may already be circulating at a low level. The study focuses on 18 pathogens selected for their potential to emerge and establish themselves in the Occitanie region: Leishmaniasis, Leptospirosis, Brucellosis, Q fever, Rickettsiosis, Tularemia, Psittacosis, Lyme disease, Tick-borne encephalitis, Hantavirus, Hepatitis E virus, Dengue virus, Zika virus, Chikungunya virus, West-Nile virus, Usutu virus, Toscana virus, Crimean-Congo haemorrhagic fever virus.\n\nThe aim of the study is to find out whether patients have antibodies against these infectious agents, which would indicate that they have been exposed to them in the past, even in the absence of symptoms.\n\nDescribing the circulation of these pathogens will enable to implement appropriate public health measures to avoid the risk of epidemics (mosquito control, informing professionals, etc.), as well as to assess the risk incurred in the workplace and have this risk recognized by the healthcare system.",[28,74,72,73,163,164,165,166,167,168,71,169,170,171,66,172,173,174],"Rickettsiosis","Tularemia","Psittacosis","Lyme Disease","Tick-borne Encephalitis","Hantaviral Infection Nos","Dengue Virus","Zika Virus","Chikungunya Virus Infection","Usutu Virus","Toscana Virus","Crimean-Congo Haemorrhagic Fever Virus",[176,74,72,177,178,179,180,181,182,183,184,185,186,187,164,165,188,189],"Leishmaniasis,","Zika virus","Q fever, Rickettsiosis","Lyme disease","Tick-borne encephaliti","Hantavirus","Hepatitis E virus","Dengue virus","Chikungunya virus","West-Nile virus","Usutu virus","Toscana virus","Crimean-Congo haemorrhagic fever virus","epidemiology","NOT_YET_RECRUITING","2025-02-27",{"date":193,"type":41},"2025-03-05",{"date":195,"type":21},"2025-03-03",{"date":197,"type":21},"2025-10-03",{"name":199,"class":146},"University Hospital, Montpellier",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":55,"sex":16,"minAge":155,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":158,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":47},"100539694","human-leishmaniasis-antigen-recognition-pattern-and-study-of-new-potential-biomarkers-100539694","NCT06307171","Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers","LeishmARPs","CASES:\n\nInclusion criteria:\n\n* Leishmania positive patient from Italy (n=30) and from Sudan (n=30);\n* patient with a clinically or laboratory confirmed diagnosis of leishmaniasis;\n* signed informed consent (criteria not applied in case of samples stored at the Tropica Biobank at the DITM)\n* being clinically classified as leishmaniasis patient by an experienced clinician or being laboratory confirmed as leishmaniasis patients, giving positive to at least two different serological tests or to a molecular test for Leishmania sp.\n* adult subjects (equal or older than 18 years)\n\nExclusion criteria:\n\n* lack of the necessary data and\u002For of biological samples\n* subjects younger than 18 years\n\nCOMMUNITY CONTROLS:\n\nInclusion criteria:\n\n* Cryo-preserved serum samples stored at the Tropica Biobank at the DITM , IRCCS Sacro Cuore Don Calabria Hospital, Negrar (Vr), from subject from Italy (n=30) and from Africa (n=30) with no infection due by Leishmania spp.\n* signed informed consent to Tropica Biobank\n* adult subjects (equal or older than 18 years)\n* being negative to two different serological tests for leishmaniasis\n\nExclusion criteria:\n\n* subjects younger than 18 years\n* being positive to one serological tests for leishmaniasis.\n\nVALIDATION CONTROLS (VC):\n\nInclusion criteria:\n\n* serum samples stored in Tropica Biobank at the DITM from subjects that have been clinically diagnosed with Chagas's disease, or TB, or malaria or leprosy.\n* informed consent signed to Tropical Biobank\n* adult subjects (equal or older than 18 years)\n* being negative to two different serological tests for leishmaniasis.\n* being clinically diagnosed with Chagas disease or TB, or malaria or leprosy\n\nExclusion criteria:\n\n* younger than 18 years\n* positive result to one serological test for leishmaniasis.",{"count":208,"type":21},170,[160],"This is an exploratory experimental multicentre study on archived serum samples and on prospectively collected serum samples and blood samples.\n\nGeneral objectives of the study are: to identify specific biomarkers in order to develop more accurate serological tests for the screening of Leishmania infections that does not present cross-reaction with other infectious diseases; to unveil the Antigen Recognition Patterns (ARPs) of Leishmania infection in humans; to verify whether the ARPs and the new biomarkers are common to different Leishmania infantum strains isolated in Italy as well as in other part of the World and to different strains of L. donovani isolated in Sudan as well as in other part of the World and discard any possible cross reaction with other infectious diseases such as Chagas, TB, leprosy or malaria.",[28],"2024-03-05",{"date":214,"type":41},"2024-03-12",{"date":216,"type":41},"2023-05-22",{"date":218,"type":21},"2026-11",{"name":220,"class":146},"IRCCS Sacro Cuore Don Calabria di Negrar"]